Table 1.
Characteristics of Participants
| Characteristic | DPX-RSV(A) (10 µg) (n = 8) | RSV(A)-Alum (10 µg) (n = 8) | DPX-RSV(A) (25 µg) (n = 8) | RSV(A)-Alum (25 µg) (n = 8) | Placebo (n = 8) | Total (n = 40) |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| Mean ± SD | 56.4 ± 4.84 | 53.4 ± 3.54 | 56.3 ± 3.99 | 56.1 ± 3.64 | 54.3 ± 3.77 | 55.3 ± 3.97 |
| Range | 50–63 | (50,60) | (51,62) | (53,63) | (50,61) | |
| Sex, no. (%) | ||||||
| Male | 1 (12.5) | 5 (62.5) | 2 (25.0) | 1 (12.5) | 2 (25.0) | 11 (27.5) |
| Female | 7 (87.5) | 3 (37.5) | 6 (75.0) | 7 (87.5) | 6 (75.0) | 29 (72.5) |
| Race, no. (%) | ||||||
| Black/African Canadian | 0 (0) | 0 (0) | 0 (0) | 1 (12.5) | 0 (0) | 1 (2.5) |
| White | 8 (100) | 8 (100) | 8 (100) | 7 (87.5) | 7 (87.5) | 38 (95.0) |
| Other | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (12.5) | 1 (2.5) |
Data are no. (%) of participants, unless otherwise indicated. See “Methods” for a description of vaccine formulations.
Abbreviations: DPX, DepoVax; RSV(A), respiratory syncytial virus subgroup A.